An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX), a leading prescription digital therapeutics company, announced that CEO Kevin Appelbaum will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on June 23, 2022, at 12:40 p.m. ET. This event will focus on their innovative approach to treating cardiometabolic diseases through nutritional cognitive behavioral therapy (nCBT). Better Therapeutics aims to provide FDA-regulated software solutions that address the root causes of conditions like type 2 diabetes and heart disease.
Positive
None.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m. ET.
The live panel will be available to registered participants in the conference. To listen to the live panel, please contact your Cowen representative.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
Better Therapeutics, Inc. (NASDAQ: BTTX) specializes in developing prescription digital therapeutics that use cognitive behavioral therapy to tackle cardiometabolic diseases.
When will Kevin Appelbaum speak at the FutureHealth Conference?
Kevin Appelbaum will participate in the panel on June 23, 2022, at 12:40 p.m. ET.
What is the focus of Better Therapeutics’ panel at the conference?
The panel will focus on commercializing prescription digital therapeutics, highlighting Better Therapeutics' innovative approaches.
How does Better Therapeutics' solution address health issues?
Their solutions aim to create lasting behavioral changes through cognitive behavioral therapy, targeting the root causes of diseases like type 2 diabetes.
Where can I find more information about Better Therapeutics?
More information can be found on their website at bettertx.com.
